...
首页> 外文期刊>International Journal of Physiology, Pathophysiology and Pharmacology >How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?
【24h】

How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?

机译:尿道前列腺癌抗原3(PCA3)水平和GLEASON评分如何在怀疑前列腺癌的情况下如何?

获取原文
           

摘要

Introduction: Prostate cancer is one of the most common cancers in men which is mostly slow growing and responses well to treatments if early diagnosed. Urinary prostate cancer antigen 3 (PCA3) assay is a new method with effective results in diagnosing prostate cancer. The aim of this present study was evaluate the correlation between urinary PCA3 and Gleason scores in patients who are suspicious of prostate cancer and undergo tissue biopsies. Methods: This is a cross-sectional study which was performed in 2017-2018. The patients included this study complain of prostate problems and were selected from Nour hospital, Ali-Asghar hospital and Ordibehesht clinic in Tehran, Iran. Urinary PCA3 levels were checked in all patients and then they went under prostate biopsies. Amounts of PCA3 and Gleason scores were collected and analyzed using SPSS software. Findings: We evaluated a total number of 80 patients. 40 patients had prostate cancer and 40 had no cancer. We indicated that no significant relation was reported between Gleason scores and urinary PCA3 levels. Levels of urinary PCA3 were higher in patients with prostate cancer than in patients with no cancer (P=0.007). Discussion: Generally, urinary PCA3 test is indicated as a non-invasive method to improve the specificity of prostate cancer diagnosis and its potential predictive value was studied in numerous clinical researches, but here we found higher PCA3 levels in patients with prostate cancer than in patients with and other prostate problems. We conclude that PCA3 functions as a diagnostic test and its changes in prostate cancer need to be further studied in different populations and races.
机译:介绍:前列腺癌是男性中最常见的癌症之一,如果早期诊断,治疗良好和对治疗的影响很大。尿癌癌抗原3(PCA3)测定是一种具有有效导致诊断前列腺癌的新方法。本研究的目的是评估尿PCA3和肠胃酵成绩的相关性,这些患者在怀疑前列腺癌并进行组织活检。方法:这是在2017 - 2018年进行的横截面研究。该研究包括这项研究抱怨前列腺问题,并选自伊朗德黑兰的Nour医院,Ali-Asghar医院和Ortibehesht诊所。在所有患者中检查了尿PCA3水平,然后在前列腺活检下进行。使用SPSS软件收集并分析PCA3和GLEASON分数的数量。调查结果:我们评估了80名患者的总数。 40名患者有前列腺癌,40名没有癌症。我们表示,在Gleason评分和泌尿PCA3水平之间没有报告重大关系。前列腺癌患者的尿PCA3水平高于没有癌症的患者(p = 0.007)。讨论:一般而言,尿PCA3试验被指示为改善前列腺癌诊断的特异性的非侵入性方法,并且在许多临床研究中研究了其潜在的预测值,但在这里我们发现前列腺癌患者的PCA3水平高于患者与其他前列腺问题。我们得出结论,PCA3用作诊断试验及其在不同群体和种族中进一步研究前列腺癌的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号